Lymphoma is a heterogeneous group of malignant neoplasms originating from the lymphohematopoietic system, with relapse, drug resistance, and treatment-related toxicity remaining major clinical challenges. Owing to their structural diversity, capacity to modulate multiple signaling nodes, and potential to reshape the tu...
Hangfan Lin, Chunyi Lyu, Teng Wang et al.· European Journal of Pharmaco...· 0 citations
Other primary malignancies (OPMs) may complicate diagnostic assessment, treatment sequencing, and prognostic evaluation in multiple myeloma (MM). This study characterized the spectrum and timing of OPMs and evaluated their association with overall survival (OS).
We retrospectively screened 461 unique patient...
Chang-Nian Li, Ya-Ru Wang, Lu-Lu Li et al.· Frontiers in Oncology· 0 citations
Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.